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Editorial
“Back to the Future” With Value in Health
Michael F. Drummond, MCom, DPhil*, Centre for Health Economics, University of York, York, England, UK
C. Daniel Mullins, PhD, Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA
For the 20th anniversary issue of Value in Health, we wanted to
reﬂect on how “value” has been deﬁned, measured, and debated
since the journal started. At the same time, Value in Health
continues to be forward-looking. We are grateful to the 2 former
Editors-in-Chief, Joel W. Hay, PhD, and Josephine Mauskopf, PhD,
MHA, for setting the trajectory for excellence in peer review, and
we are proud of the impact that Value in Health has made on the
ﬁeld of health economics and outcomes research (HEOR) as we
celebrate the journal’s achievements over the past 20 years.
In planning this special anniversary issue, we issued a call for
papers to attract submissions on value-related topics that have
been widely discussed in Value in Health over the past 2 decades
and for which there remain current debate and an exciting future
agenda. More than 60 articles were submitted for this 20th
anniversary issue, and we selected 17 articles on the basis of our
peer-review process. The selected articles discuss various topics,
which we have categorized under 3 main themes: Notions of
“Value” in Healthcare, Decision-Analytic Modeling, and HEOR in the
Broader Context of Health Technology Assessment (HTA) and
Comparative-Effectiveness Research.
Notions of “Value” in Healthcare
The journal’s title is a good reminder that the notion of “value”
has different connotations and reﬂects clinical, economic, and
health-related quality-of-life components. Certainly, the debate
surrounding the use of cost per quality-adjusted life-year remains
a highly controversial and at times political concern. The notions
of value are interdependent on measurement and so regardless of
how value is deﬁned, there remain controversies regarding both
the numerator (ie, measurement of costs) and the denominator
(ie, measurement of effectiveness or beneﬁts). The articles
grouped under the Notions of “Value” in Healthcare section discuss
those components, as well as the role of patient-reported out-
comes as one of the central notions of deﬁning and assessing
value.
Many governments around the world have also been interested
in knowing how to assess value in healthcare. There are several
international agencies that are responsible for value assessments
and their approaches have been debated in both academic and
policy arenas. The “reference case” also has been widely debated
from both a scientiﬁc and a pragmatic lens. Some of the contro-
versies that were being debated 20 years ago have been resolved
to a large extent, whereas other notions of value remain as
controversial in 2019 as they were at the turn of the century.
The science of HEOR has certainly evolved over the past 2
decades and ISPOR has been a major driver of some of that
scientiﬁc advancement. Value in Health remains committed to
publishing the best methodological and empirical HEOR articles,
including reports by ISPOR task forces that aim “to develop expert
consensus guidance reports on international good practice
standards for HEOR and on the use of this research in healthcare
decision making.”1
Decision-Analytic Modeling
Decision-analytic modeling is a central feature of HEOR and
has been a major theme in the journal since its inception. We have
published numerous empirical studies in all ﬁelds of medicine, but
perhaps the major contribution to the literature has been in the
development of methodological standards. The journal has pub-
lished a number of articles discussing the pros and cons of
different modeling approaches and published the outputs of the 2
ISPOR Good Research Practices task forces on modeling,2,3 the
second jointly with the Society for Medical Decision Making,3
which have outlined the standards to which all analysts should
aspire.
For this anniversary issue, we commissioned articles from the
journal’s 2 previous Editors-in-Chief, both of whom focused on the
modeling theme. The article from our founding Editor-in-Chief,
Joel W. Hay, stresses the need for more transparency in
modeling if it is to gain sufﬁcient credibility, especially among
decision makers in the United States. The article by our second
Editor-in-Chief, Josephine Mauskopf, analyzes the journal’s
contribution to the literature on guidelines for multivariable and
structural uncertainty in cost-effectiveness analyses. She argues
that, in the future, we can expect more consideration of different
methods for combining multivariable and structural uncertainty
analyses, as part of a continued evolution of uncertainty analyses
in published studies, consistent with the goal of providing more
useful information to decision makers.
Looking to the future, we see no diminution in the role
decision-analytic modeling will play in the journal. In the case of
pharmaceuticals, the existence of accelerated approval has led to
products being approved with less mature clinical data, and the
growth in specialty pharmaceutical products has led to a greater
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need for evidence synthesis and a greater role for data collected
postapproval. In addition, there is a growing interest in the eval-
uation of medical devices and procedures, which, because of a
different approach to regulation, are less likely to have well-
controlled clinical studies and consequently have a greater
reliance on observational data to demonstrate their clinical
effectiveness. All these developments suggest a strong role for
modeling going forward, with a particular emphasis on new
methods to analyze real-world data.
An important development, which is just beginning, is the
increased role of machine learning and artiﬁcial intelligence in
decision-analytic modeling. This is likely to be particularly
important in the analysis of large, real-world data sets and should
lead to increased efﬁciency in modeling and in the provision of
healthcare itself. We expect to publish many more articles on
these topics in the future.
HEOR in the Broader Context of HTA and
Comparative-Effectiveness Research
Throughout the journal’s history, we have published a number
of articles discussing the role of HEOR in the broader context of
HTA and comparative-effectiveness research, including the
contribution of all these subdisciplines to informing clinical de-
cision making and health policy. As in the case of decision-analytic
modeling, the journal has published a large number of empirical
studies. In addition, we have contributed to the literature on
developing methodological standards and on good practice,
including improving transparency and increasing stakeholder
involvement. The journal has also published a number of articles
that compare the practice of different HTA bodies in their use of
cost-effectiveness data. Over the years, it has become apparent
that there are key national differences that inﬂuence the extent of
the use of HTA and how it is practiced. We expect to publish more
articles exploring these issues as the use of HTA spreads to other
countries and regions worldwide.
In the future we also expect to receive more submissions dis-
cussing the methodological and practical challenges of using
HEOR in decisions about the reimbursement of health technolo-
gies. The changes in the regulation of new medicines, including
the aforementioned accelerated approval processes, mean that
early dialogue between regulators, manufacturers, and HTA bodies
is increasingly important and that the balance of data collection
on clinical and cost-effectiveness will shift more toward post-
launch and include a greater role for real-world data.
In addition, the increased uncertainty about clinical effective-
ness and cost-effectiveness suggests that the current interest in
managed entry agreements is unlikely to be reduced. In fact, with
the advent of more new therapies with curative intent, having the
potential for high initial budgetary impact, there is an even greater
need to develop innovative approaches for the adoption of these
therapies. Therefore, we expect to publish more articles discussing
the various types of managed entry schemes in the future.
Looking Forward to the Future
As the current Editors-in-Chief, we are proud of what Value in
Health has achieved over the past 20 years. Nevertheless, like the
individual researchers whose articles it receives, the journal is
only as good as the next article it publishes. Therefore, we see our
role as maintaining the high standards that the journal has already
established, and hopefully improving on them. A key part of this
task is to anticipate the changes we are likely to see in the ﬁeld of
HEOR as the environment for healthcare products and services
changes in the future. The changes will be partly reﬂected in the
articles we receive, but we also intend to use our themed sections
to make the journal content as relevant and as current as we can.
If we can achieve that, Value in Health will continue to deliver
“value” to its readers and its authors well into the future.
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